Stryker (SYK) Competitors $368.40 +2.13 (+0.58%) As of 12:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SYK vs. CSQ, ISRG, BSX, CAH, COR, DVA, MDT, ZBH, ABT, and BDXShould you be buying Stryker stock or one of its competitors? The main competitors of Stryker include Calamos Strategic Total Return Fund (CSQ), Intuitive Surgical (ISRG), Boston Scientific (BSX), Cardinal Health (CAH), Cencora (COR), DaVita (DVA), Medtronic (MDT), Zimmer Biomet (ZBH), Abbott Laboratories (ABT), and Becton, Dickinson and Company (BDX). Stryker vs. Its Competitors Calamos Strategic Total Return Fund Intuitive Surgical Boston Scientific Cardinal Health Cencora DaVita Medtronic Zimmer Biomet Abbott Laboratories Becton, Dickinson and Company Calamos Strategic Total Return Fund (NASDAQ:CSQ) and Stryker (NYSE:SYK) are related companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability. Is CSQ or SYK more profitable? Stryker has a net margin of 12.25% compared to Calamos Strategic Total Return Fund's net margin of 0.00%. Stryker's return on equity of 23.94% beat Calamos Strategic Total Return Fund's return on equity.Company Net Margins Return on Equity Return on Assets Calamos Strategic Total Return FundN/A N/A N/A Stryker 12.25%23.94%11.08% Is CSQ or SYK a better dividend stock? Calamos Strategic Total Return Fund pays an annual dividend of $1.23 per share and has a dividend yield of 6.4%. Stryker pays an annual dividend of $3.36 per share and has a dividend yield of 0.9%. Stryker pays out 44.5% of its earnings in the form of a dividend. Stryker has increased its dividend for 32 consecutive years. Do institutionals & insiders believe in CSQ or SYK? 77.1% of Stryker shares are owned by institutional investors. 5.2% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts recommend CSQ or SYK? Stryker has a consensus target price of $430.10, suggesting a potential upside of 16.79%. Given Stryker's stronger consensus rating and higher probable upside, analysts clearly believe Stryker is more favorable than Calamos Strategic Total Return Fund.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calamos Strategic Total Return Fund 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Stryker 0 Sell rating(s) 6 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.71 Does the media favor CSQ or SYK? In the previous week, Stryker had 39 more articles in the media than Calamos Strategic Total Return Fund. MarketBeat recorded 40 mentions for Stryker and 1 mentions for Calamos Strategic Total Return Fund. Stryker's average media sentiment score of 1.60 beat Calamos Strategic Total Return Fund's score of 1.00 indicating that Stryker is being referred to more favorably in the news media. Company Overall Sentiment Calamos Strategic Total Return Fund Positive Stryker Very Positive Which has stronger valuation & earnings, CSQ or SYK? Stryker has higher revenue and earnings than Calamos Strategic Total Return Fund. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalamos Strategic Total Return Fund$280.21MN/AN/AN/AN/AStryker$22.60B6.23$2.99B$7.5548.78 SummaryStryker beats Calamos Strategic Total Return Fund on 12 of the 14 factors compared between the two stocks. Get Stryker News Delivered to You Automatically Sign up to receive the latest news and ratings for SYK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SYK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYK vs. The Competition Export to ExcelMetricStrykerMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$140.95B$10.71B$6.13B$21.92BDividend Yield0.91%1.86%5.51%3.56%P/E Ratio48.8322.2285.5229.61Price / Sales6.2327.52585.1099.18Price / Cash24.5625.6126.3018.33Price / Book6.803.4613.164.60Net Income$2.99B$210.63M$3.30B$1.01B7 Day Performance-0.31%1.82%4.71%0.11%1 Month Performance-6.06%1.40%8.36%2.22%1 Year Performance6.70%-5.70%87.42%13.68% Stryker Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYKStryker4.9635 of 5 stars$368.41+0.6%$430.10+16.7%+4.2%$140.90B$22.60B48.8153,000Positive NewsAnalyst ForecastCSQCalamos Strategic Total Return FundN/A$19.21+0.3%N/A+11.6%$0.00$280.21M0.00N/APositive NewsDividend AnnouncementISRGIntuitive Surgical4.9557 of 5 stars$439.22-0.4%$595.95+35.7%-6.7%$157.45B$8.35B61.2615,638Positive NewsAnalyst UpgradeBSXBoston Scientific4.9299 of 5 stars$96.89-1.3%$118.38+22.2%+14.4%$143.57B$16.75B57.6753,000Analyst ForecastCAHCardinal Health4.9371 of 5 stars$154.79+0.7%$165.93+7.2%+38.6%$36.77B$222.58B24.0057,700Trending NewsAnalyst ForecastAnalyst RevisionCORCencora4.5568 of 5 stars$308.12+0.4%$311.25+1.0%+38.8%$59.74B$293.96B31.7046,000Trending NewsAnalyst RevisionDVADaVita4.8105 of 5 stars$130.66-0.1%$158.00+20.9%-20.2%$9.34B$12.82B12.8576,000Positive NewsMDTMedtronic4.8286 of 5 stars$94.00-0.2%$102.27+8.8%+11.6%$120.57B$33.54B25.8995,000Positive NewsAnalyst ForecastZBHZimmer Biomet4.7305 of 5 stars$98.13-0.1%$113.16+15.3%-5.5%$19.44B$7.68B23.8817,000Positive NewsABTAbbott Laboratories4.96 of 5 stars$133.01-0.4%$145.22+9.2%+18.6%$231.49B$41.95B16.67114,000Positive NewsBDXBecton, Dickinson and Company4.9214 of 5 stars$183.85-0.4%$213.09+15.9%-19.4%$52.70B$20.18B33.0774,000Positive News Related Companies and Tools Related Companies CSQ Alternatives ISRG Alternatives BSX Alternatives CAH Alternatives COR Alternatives DVA Alternatives MDT Alternatives ZBH Alternatives ABT Alternatives BDX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:SYK) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stryker Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Stryker With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
